The anti-platelet drug cilostazol enhances heart rate and interrenal steroidogenesis and exerts a scant effect on innate immune responses in zebrafish

WC Chang, MJ Chen, CD Hsiao, RZ Hu, YS Huang… - Plos one, 2023 - journals.plos.org
Rationale Cilostazol, an anti-platelet phosphodiesterase-3 inhibitor used for the treatment of
intermittent claudication, is known for its pleiotropic effects on platelets, endothelial cells and …

Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder

FE Padovan-Neto, AJO Cerveira, A da Silva… - …, 2024 - nature.com
Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental conditions
characterized by differences in social communication and interaction, coupled with repetitive …

The challenge of managing difficult to treat psychiatric conditions

A Serretti - International Clinical Psychopharmacology, 2023 - journals.lww.com
Autism spectrum disorder (ASD) is part of these cases; an integrative therapeutic approach
is usually suggested, and a range of treatments showed a variable degree of benefit (Howes …

The anti-platelet drug cilostazol enhances interrenal steroidogenesis and exerts a scant effect on innate immune responses in zebrafish

WC Chang, MJ Chen, YF Chen, CW Chou, YJ Chuang… - bioRxiv, 2022 - biorxiv.org
Rationale Cilostazol, an anti-platelet phosphodiesterase-3 inhibitor used for the treatment of
intermittent claudication, is known for its pleiotropic effects on platelets, endothelial cells and …